Login to Your Account

OPKO Flips Nausea Drug Rolapitant to Tesaro for $121M

By Catherine Shaffer

Wednesday, December 15, 2010
Tesaro Inc. has acquired rights to nausea drug rolapitant and one other drug from OPKO Health Inc. for $121 million Including milestones, double-digit, tiered royalties and a 10 percent equity position in Tesaro. Rolapitant was a Schering-Plough Corp. property, but OPKO nabbed it for just $2 million up front following Schering's 2009 merger with Merck and Co. Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription